Company: Oryzon Genomics
Job title: Drug Discovery Director
Robert Soliva holds a BSc in Molecular Biology/Biochemistry and a PhD in Computational Chemistry from University of Barcelona and Institute of Research in Biomedicine-IRB Barcelona. He has ample experience in Drug Discovery and thorough knowledge of IP law acquired in Uriach Labs/Palau Pharma and ZBM Patents&Trademarks. In 2016 he co-founded the computational chemistry company Nostrum Biodiscovery, where he acted as CSO and CEO, and recently joined Oryzon Genomics as Director of Drug Discovery.
Modulation of the Lysine Specific Demethylase 1 with iadademstat and vafidemstat: Cancer, Cognition and Behavior 9:45 am
Inhibition of LSD1 by irreversible binding to the FAD cofactor Iadademstat for treatment of AML and SCLC Increased of neuronal plasticity and improvement of cognitive and behavioral functions by treatment with vafidemstat Modulation of LSD1 activity as a personalized medicine strategy in CNS disease.Read more
day: Virtual Conference Day